Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmidt, A.
Right arrow Articles by Mayer, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, A.
Right arrow Articles by Mayer, G.

Journal of the American Society of Nephrology, Vol 7, 314-317, Copyright © 1996 by American Society of Nephrology

REGULAR ARTICLES

Angiotensin-converting enzyme polymorphism in patients with terminal renal failure

A Schmidt, HP Kiener, U Barnas, I Arias, A Illievich, M Auinger, W Graninger, A Kaider and G Mayer
Department of Nephrology, University of Vienna, Austria.

An insertion/deletion polymorphism has been described for the gene that encodes the angiotensin-converting enzyme. The deletion allele is associated with higher angiotensin-converting enzyme plasma levels, which ultimately might lead to increased angiotensin II concentrations. Because angiotensin II is a mediator for progressive renal injury, this study determined the frequency of distribution of the angiotensin- converting enzyme insertion/deletion polymorphism in 106 hemodialysis patients and in a group of 95 healthy control patients. There was no difference between the two groups as far as the distribution of the insertion and deletion allele was concerned. Of the total hemodialysis population, 26.4% exhibited the deletion/deletion genotype, as compared with 37.9% of the healthy control population. Also, when patients with terminal renal failure as a result of glomerular disease were analyzed separately, the frequency of the deletion/deletion genotype was identical to that of the control group. Furthermore, the frequency of hypertension, coronary artery disease, left ventricular hypertrophy, and dilated cardiomyopathy, were analyzed according to the angiotensin- converting enzyme genotype, but the deletion allele could not be defined as a risk factor in the study's hemodialysis population. It was therefore concluded that the angiotensin-converting enzyme insertion/deletion polymorphism is not a major risk factor for development of end-stage renal failure. Additionally, in hemodialysis patients, there is no association between the risk for cardiovascular diseases and the angiotensin-converting enzyme genotype.


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
M. Buraczynska, P. Ksiazek, A. Drop, W. Zaluska, D. Spasiewicz, and A. Ksiazek
Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease
Nephrol. Dial. Transplant., April 1, 2006; 21(4): 979 - 983.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
A. Anvari, Z. Turel, A. Schmidt, N. Yilmaz, G. Mayer, K. Huber, E. Schuster, and M. Gottsauner-Wolf
Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphism in coronary disease and malignant ventricular arrhythmias
Cardiovasc Res, September 1, 1999; 43(4): 879 - 883.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673